secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001437749-25-005799
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton launches Galzin (zinc acetate) capsules for Wilson disease maintenance therapy
--------------------------------------------------------------------------------

- Galzin is FDA-approved for maintenance treatment of Wilson disease after chelator therapy; only FDA-approved zinc therapy for Wilson disease.
- Exclusive distribution through Optime Care; Eton Cares program offers $0 co-pay, insurance benefits investigation, and educational support.
- CEO Sean Brynjelsen states dedicated sales force and patient support aim to expand access beyond unapproved compounded products.
- Eton is investing in further R&D to drive meaningful advancements in Wilson disease treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925005799/0001437749-25-005799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925005799/eton20250225_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-005799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer